Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial

Georgina V. Long(Royal North Shore Hospital), Robyn P.M. Saw(Melanoma Institute Australia), Serigne Lo(Melanoma Institute Australia), Omgo E. Nieweg(University of Sydney), Kerwin F. Shannon(Royal Prince Alfred Hospital), Maria Gonzalez(Melanoma Institute Australia), Alexander Guminski(Melanoma Institute Australia), Jenny Lee(Macquarie University), Hansol Lee(Melanoma Institute Australia), Peter M. Ferguson(University of Sydney), Robert V. Rawson(University of Sydney), James S. Wilmott(Melanoma Institute Australia), John F. Thompson(Royal Prince Alfred Hospital), Richard Kefford(Melanoma Institute Australia), Sydney Ch’ng(University of Sydney), Jonathan R. Stretch(Melanoma Institute Australia), Louise Emmett(St Vincent's Hospital Sydney), Rony Kapoor(Mater Health Services), Helen Rizos(Macquarie University), Andrew J. Spillane(Melanoma Institute Australia), Richard A. Scolyer(Melanoma Institute Australia), Alexander M. Menzies(University of Sydney)

The Lancet Oncology

June 3, 2019

Cited by 185

Abstract

No related papers found

Powered by citation graph analysis